85 related articles for article (PubMed ID: 17514825)
1. Autoantibody signatures: a promising new test for prostate cancer.
Harv Mens Health Watch; 2007 May; 11(10):7. PubMed ID: 17514825
[No Abstract] [Full Text] [Related]
2. Identifying novel autoantibody signatures in ovarian cancer using high-density protein microarrays.
Gunawardana CG; Memari N; Diamandis EP
Clin Biochem; 2009 Mar; 42(4-5):426-9. PubMed ID: 19094976
[TBL] [Abstract][Full Text] [Related]
3. A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: Inflammation in their induction and impact on tumor growth.
Bei R; Masuelli L; Palumbo C; Modesti M; Modesti A
Cancer Lett; 2009 Aug; 281(1):8-23. PubMed ID: 19091462
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of prostate cancer.
Doehn C
Eur Urol; 2008 Apr; 53(4):681-3; discussion 684-5. PubMed ID: 18248878
[No Abstract] [Full Text] [Related]
5. Antiprostasome antibodies are not an appropriate prognostic marker for prostate cancer.
Stewart AB; Delves GH; Birch BR; Cooper AJ; Lwaleed BA
Scand J Urol Nephrol; 2009; 43(2):104-8. PubMed ID: 18979375
[TBL] [Abstract][Full Text] [Related]
6. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
7. Immunological prostate cancer test developed.
J Med Assoc State Ala; 1973 Oct; 43(4):278. PubMed ID: 4583455
[No Abstract] [Full Text] [Related]
8. Increased levels of IgG antibodies against peptides of the prostate stem cell antigen in the plasma of pancreatic cancer patients.
Tanaka M; Komatsu N; Terakawa N; Yanagimoto Y; Oka M; Sasada T; Mine T; Gouhara S; Shichijo S; Okuda S; Itoh K
Oncol Rep; 2007 Jul; 18(1):161-6. PubMed ID: 17549363
[TBL] [Abstract][Full Text] [Related]
9. Harnessing immunity for cancer marker discovery.
Hanash S
Nat Biotechnol; 2003 Jan; 21(1):37-8. PubMed ID: 12511908
[No Abstract] [Full Text] [Related]
10. Immunotherapeutics in development for prostate cancer.
Harzstark AL; Small EJ
Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
[TBL] [Abstract][Full Text] [Related]
11. Current immunotherapeutic strategies in prostate cancer.
Grosso JF; Drake CG
Surg Oncol Clin N Am; 2007 Oct; 16(4):861-71, x. PubMed ID: 18022549
[TBL] [Abstract][Full Text] [Related]
12. Identifying autoantibody signatures in cancer: a promising challenge.
Desmetz C; Maudelonde T; Mangé A; Solassol J
Expert Rev Proteomics; 2009 Aug; 6(4):377-86. PubMed ID: 19681673
[TBL] [Abstract][Full Text] [Related]
13. Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer.
Olson BM; McNeel DG
Prostate; 2007 Dec; 67(16):1729-39. PubMed ID: 17879963
[TBL] [Abstract][Full Text] [Related]
14. Interview with Jack Schalken. PCA3 and its use as a diagnostic test in prostate cancer. Interview by Christine McKillop.
Schalken J
Eur Urol; 2006 Jul; 50(1):153-4. PubMed ID: 16713069
[No Abstract] [Full Text] [Related]
15. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.
Garcia-Hernandez Mde L; Gray A; Hubby B; Klinger OJ; Kast WM
Cancer Res; 2008 Feb; 68(3):861-9. PubMed ID: 18245488
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of the metabolome suggests a major potential role of sarcosine in the progression of cancer of the prostate].
Darbon JM
Bull Cancer; 2009 Apr; 96(4):355-6. PubMed ID: 19562840
[No Abstract] [Full Text] [Related]
17. ProstaScint and its role in the diagnosis of prostate cancer.
Mohammed AA; Shergill IS; Vandal MT; Gujral SS
Expert Rev Mol Diagn; 2007 Jul; 7(4):345-9. PubMed ID: 17620043
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers for prostate cancer detection.
Parekh DJ; Ankerst DP; Troyer D; Srivastava S; Thompson IM
J Urol; 2007 Dec; 178(6):2252-9. PubMed ID: 17936845
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
